This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tseng, J. E. Articles by Mao, L. Search for Related Content PubMed PubMed Citation Articles by Tseng, J. E. Articles by Mao, L.

Loss of Fhit Is Frequent in Stage I Non-Small Cell Lung Cancer and in the Lungs of Chronic Smokers¹

Molecular Biology Laboratory at the Department of Thoracic/Head and Neck Medical Oncology [J. E. T., F. R. K., J. M. K., J. S. L., X. Z., D. L., W. K. H., L. M.] and the Department of Pathology [B. L. K.], the University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Abnormalities of FHIT, a candidate tumor suppressor gene at 3p14.2, have been found frequently in multiple tumor types including non-small cell lung cancer (NSCLC). To investigate whether FHIT inactivation plays a role in early lung tumorigenesis, Fhit levels were determined by immunohistochemistry in tumors from 87 patients with stage I NSCLC and in 372 bronchial biopsy specimens from 86 chronic smokers without evidence of malignancy. We found that 49% of NSCLC specimens demonstrated significantly decreased staining or lack of staining for Fhit. However, Fhit expression status was not significantly associated with disease-free survival or overall survival. Analysis of a subset of 76 specimens on which microsatellite analysis at the FHIT locus was performed did not show a strong association between loss of heterozygosity at FHIT and Fhit expression, suggesting the presence of complex mechanisms of Fhit inactivation. Of 372 bronchial biopsies from chronic smokers, 86 biopsies (23%) exhibited decreased Fhit expression or lack of Fhit expression. In 37 of 86 (43%) subjects, decreased Fhit expression or lack of expression was observed in at least one biopsy site. Loss of Fhit expression was significantly higher in bronchial metaplastic lesions (23 of 49 lesions, 47%) than in histologically normal bronchial epithelium (63 of 323 specimens, 20%; P < 0.001). Smokers with a metaplasia index of >15% had a higher frequency of loss of Fhit expression than those with a metaplasia index of 15% (P = 0.015). Interestingly, current smokers had a higher rate of loss of Fhit expression than former smokers (P = 0.02). Our data indicate that Fhit expression is significantly reduced in a substantial number of early-stage NSCLC and preneoplastic lesions in chronic smokers. The association between cigarette smoking and Fhit expression suggests a role for FHIT in the initiation of smoking-related lung tumorigenesis.

This article has been cited by other articles:

				P. Bavi, Z. Jehan, V. Atizado, H. Al-Dossari, F. Al-Dayel, A. Tulbah, S. S. Amr, S. S. Sheikh, A. Ezzat, H. El-Solh, et al. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1708 - 1718. [Abstract] [Full Text] [PDF]

				F. D'Agostini, A. Izzotti, R. Balansky, N. Zanesi, C. M. Croce, and S. De Flora Early loss of fhit in the respiratory tract of rodents exposed to environmental cigarette smoke. Cancer Res., April 1, 2006; 66(7): 3936 - 3941. [Abstract] [Full Text] [PDF]

				K. Mimori, H. Ishii, H. Nagahara, T. Sudo, K. Yamashita, H. Inoue, G. F. Barnard, and M. Mori FHIT Is Up-Regulated by Inflammatory Stimuli and Inhibits Prostaglandin E2-Mediated Cancer Progression. Cancer Res., March 1, 2006; 66(5): 2683 - 2690. [Abstract] [Full Text] [PDF]

				U.-P. Rohr, N. Rehfeld, H. Geddert, L. Pflugfelder, I. Bruns, J. Neukirch, A. Rohrbeck, H. J. Grote, U. Steidl, R. Fenk, et al. Prognostic Relevance of Fragile Histidine Triad Protein Expression in Patients with Small Cell Lung Cancer Clin. Cancer Res., January 1, 2005; 11(1): 180 - 185. [Abstract] [Full Text] [PDF]

				C. Lu, J.-C. Soria, X. Tang, X.-C. Xu, L. Wang, L. Mao, R. Lotan, B. Kemp, B. N. Bekele, L. Feng, et al. Prognostic Factors in Resected Stage I Non-Small-Cell Lung Cancer: A Multivariate Analysis of Six Molecular Markers J. Clin. Oncol., November 15, 2004; 22(22): 4575 - 4583. [Abstract] [Full Text] [PDF]

				J. S. Kim, H. Kim, Y. M. Shim, J. Han, J. Park, and D.-H. Kim Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung Carcinogenesis, November 1, 2004; 25(11): 2165 - 2171. [Abstract] [Full Text] [PDF]

				C. Mascaux, B. Martin, J.M. Verdebout, A.P. Meert, V. Ninane, and J.P. Sculier Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53 Eur. Respir. J., May 1, 2003; 21(5): 753 - 758. [Abstract] [Full Text] [PDF]

				R. Danesi, F. De Braud, S. Fogli, T. M. De Pas, A. Di Paolo, G. Curigliano, and M. Del Tacca Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer Pharmacol. Rev., March 1, 2003; 55(1): 57 - 103. [Abstract] [Full Text] [PDF]

				Y. S. Chang, L. Wang, D. Liu, L. Mao, W. K. Hong, F. R. Khuri, and H.-Y. Lee Correlation between Insulin-like Growth Factor-binding Protein-3 Promoter Methylation and Prognosis of Patients with Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., December 1, 2002; 8(12): 3669 - 3675. [Abstract] [Full Text] [PDF]

				K. Uematsu, A. Yoshimura, A. Gemma, H. Mochimaru, Y. Hosoya, S. Kunugi, K. Matsuda, M. Seike, F. Kurimoto, K. Takenaka, et al. Aberrations in the Fragile Histidine Triad (FHIT) Gene in Idiopathic Pulmonary Fibrosis Cancer Res., December 1, 2001; 61(23): 8527 - 8533. [Abstract] [Full Text] [PDF]

				T. Tsujiuchi, Y. Sasaki, N. Murata, M. Tsutsumi, Y. Konishi, and D. Nakae FHIT alterations in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats Carcinogenesis, December 1, 2001; 22(12): 2017 - 2022. [Abstract] [Full Text] [PDF]

				H. Ishii, K. R. Dumon, A. Vecchione, L. Y. Y. Fong, R. Baffa, K. Huebner, and C. M. Croce Potential Cancer Therapy With the Fragile Histidine Triad Gene: Review of the Preclinical Studies JAMA, November 21, 2001; 286(19): 2441 - 2449. [Abstract] [Full Text] [PDF]

				S. Zöchbauer-Müller, K. M. Fong, A. Maitra, S. Lam, J. Geradts, R. Ashfaq, A. K. Virmani, S. Milchgrub, A. F. Gazdar, and J. D. Minna 5' CpG Island Methylation of the FHIT Gene Is Correlated with Loss of Gene Expression in Lung and Breast Cancer Cancer Res., May 1, 2001; 61(9): 3581 - 3585. [Abstract] [Full Text]

				J. Brognard, A. S. Clark, Y. Ni, and P. A. Dennis Akt/Protein Kinase B Is Constitutively Active in Non-Small Cell Lung Cancer Cells and Promotes Cellular Survival and Resistance to Chemotherapy and Radiation Cancer Res., May 1, 2001; 61(10): 3986 - 3997. [Abstract] [Full Text]